A randomized controlled trial of Roxadustat in anemia of cirrhosis of liver and it's effects on HIF-1-alpha level.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230619004

Enrollment

105

Registered

2023-06-19

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia in patients with Cirrhosis of liver Effects of Roxadustat in correcting anemia in cirrhosis. Anemia Cirrhosis of Liver Roxadustat HIF-1-alpha EPO level

Interventions

Every 3 selected participants will be enrolled into one block .Simple Randomization will be done in each block by lottery method. After randomization two participants will be selected in Roxadustat tr

erythropoietin (EPO) level .,Every 3 selected participants will be enrolled into one block .Simple Randomization will be done in each block by lottery method. After randomization two participants will

erythropoietin (EPO) level .

Active Comparator Drug,Sham Comparator Other

Roxadustat 50 mg,Standard Medical Care

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cirrhosis of liver (Child pugh A or B) with anemia as defined by WHO 2. Age: 18 to 60 years.

Exclusion criteria

Exclusion criteria: 1. Patients with Child Pugh C liver cirrhosis 2. Haemoglobin level <7 gm/dl 3. Hepatocellular carcinoma 4. Pregnancy 5. Active variceal bleeding 6. Adult polycystic kidney disease 7. Hypo/Hyperthyroidism 8. Systemic Hypertension 9. Hyperkalemia 10. Patient with co-morbid condition (COPD, CKD, CCF, MI etc.) 11. Anemia caused by other haematological disorder associated with cirrhosis of liver.

Design outcomes

Primary

Measure	Time frame
Haemoglobin level, 3rd & 6th weeks from Baseline Laboratory analysis	—

Secondary

Measure	Time frame
EPO level,HIF 1 alpha level,Reticulocyte count 3rd & 6th week from Baseline Laboratory analysis	—

Countries

Bangladesh

Contacts

Public ContactDr.Md. Hasan

Bangabandhu Sheikh Mujib Medical University, Shahbag

mahsab4jan@gmail.com01716062164

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A randomized controlled trial of Roxadustat in anemia of cirrhosis of liver and it&#039;s effects on HIF-1-alpha level.